Furthermore, compared with the reference group (the subjects with no FAS and with normal blood cholesterol levels, see Table 4), the reduction in urinary 8-OHdG/Cr levels was 0.14 ± 0.79, 1.67 ± 0.36, and 2.66 ± 0.77 ng/mg in subjects who did not take FA but had hypercholesterolemia, and subjects who took FA but had normal cholesterol levels, as well as subjects with hypercholesterolemia and FAS, respectively. This evidence concerns the gene FAS and Hypercholesterolemia.